$PHAT News

Phathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone

Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est

Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate

Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25

Phathom Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability

Phathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Phathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Phathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est

Phathom Pharmaceuticals Earnings Review: Q4 Summary

Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026